Ibrutinib and Venetoclax in CLL/SLL: Long-Term Outcomes After Frontline CAPTIVATE

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study tracks long-term health outcomes for patients with CLL or SLL who were treated with ibrutinib plus venetoclax in CAPTIVATE. Researchers will document subsequent therapies after frontline treatment, monitor long-term safety, and assess how the disease may develop resistance over time. The study focuses on real-world, post-frontline experiences to understand durability and subsequent care. Data collection centers on patients’ treatments, adverse events, and disease status during follow-up. It is conducted at participating centers with prior CAPTIVATE enrollment.

Why it matters

Who can join: the full rules

Individuals who meet all of the inclusion criteria will be eligible to participate in the study.

1. Participant is willing and able to give informed consent for participation in this study.
2. Previously enrolled into the CAPTIVATE study.
3. Being treated in a center that has agreed to participate in this follow-up study.

Exclusion Criteria:

The only exclusion criterion of this study:

1\. Inability or refusal to provide informed consent.

Where it's running

• IRCCS Ospedale San Raffaele
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Paolo Ghia, Prof
• Email: ghia.paolo@hsr.it
• Phone: +39 02 26433919

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Immune profiling during first-line pirtobrutinib treatment for CLL/SLL

  This will test pirtobrutinib as a first treatment for adults with CLL or SLL and see how it changes immune cells in the blood and lymph nodes.

  Recruiting Early Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07428707

• NX-5948 treatment for adults with CLL or SLL after prior BTK and BCL-2 inhibitor therapy

  NX-5948, an oral BTK degrader, will be tried to see if it helps adults with relapsed or refractory CLL or SLL who have already been treated with both BTK and BCL-2 inhibitors.

  Recruiting at 43 sites Phase 2 Nurix Therapeutics, Inc. · Phoenix, Arizona and 42 other locations · NCT07221500

• Quality of life and symptom changes over two years in adults with CLL or SLL starting targeted therapy

  This study will see how quality of life, fatigue, and symptoms change over two years for adults with CLL or SLL who start treatment with a BTK inhibitor versus a BCL2 inhibitor.

  Recruiting H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07030400

• Acalabrutinib and Venetoclax for relapsed CLL/SLL after initial BTKi+BCL2i response

  This trial tests a finite-duration combination of acalabrutinib and venetoclax in adults whose CLL or SLL has relapsed after a first-line BTKi+BCL2i therapy and who had at least 2 years of response.

  Recruiting at 16 sites Phase 2 AstraZeneca · Boston, Massachusetts and 46 other locations · NCT07024706

• Long-term safety of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

  This study is testing the long-term safety of a treatment called lisocabtagene maraleucel in people with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Milwaukee, Wisconsin · NCT06788639

• Combination of zanubrutinib and venetoclax for treating chronic lymphocytic leukemia

  This study is testing if combining the drugs zanubrutinib and venetoclax can help adults with chronic lymphocytic leukemia who have already been treated feel better and manage their disease.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Scarborough, Maine and 3 other locations · NCT05168930

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.